Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Indaptus Therapeutics, Inc. Common Stock (INDP)

Pharmaceutical Preparations

https://www.indaptusrx.com

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.

3 COLUMBUS CIRCLE, 15TH FLOOR
NEW YORK, NY

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

08/04/2021

Market Cap

16,926,854

Shares Outstanding

8,400,000

Weighted SO

8,401,047

Total Employees

N/A

Upcoming Earnings

08/12/2024

Beta

1.1930

Last Div

0.0000

Range

1.56-4.08

Chg

-0.0100

Avg Vol

21196

Mkt Cap

16926854

Exch

NASDAQ

Country

US

Phone

347 480 9760

DCF Diff

0.0903

DCF

1.5697

Div Yield

0.0000

P/S

8779.4886

EV Multiple

-0.5920

P/FV

2.3001

Div Yield %

0.0000

P/E

-0.9007

PEG

0.0831

Payout

0.0000

Current Ratio

3.8840

Quick Ratio

3.8840

Cash Ratio

3.7871

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

110496.0574

CCC

-110496.0574

Gross Margin

0.2863

Op Margin

-8547.8086

Pretax Margin

-8167.5887

Net Margin

-8167.5887

Eff Tax Rate

0.2629

ROA

-1.9389

ROE

-1.4670

ROCE

-2.6608

NI/EBT

1.0000

EBT/EBIT

0.9555

EBIT/Rev

-8547.8086

Debt Ratio

0.0161

D/E

0.0212

LT Debt/Cap

0.0045

Total Debt/Cap

0.0208

Int Coverage

-81.6141

CF/Debt

-97.0794

Equity Multi

1.3172

Rec Turnover

0.0000

Pay Turnover

0.0033

Inv Turnover

0.0000

FA Turnover

0.0150

Asset Turnover

0.0002

OCF/Share

-1.4862

FCF/Share

-1.4862

Cash/Share

0.8546

OCF/Sales

-6586.1929

FCF/OCF

1.0000

CF Coverage

-97.0794

ST Coverage

-123.0170

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

2.3001

P/B

2.3001

P/S

8779.4886

P/E

-0.9007

P/FCF

-1.3330

P/OCF

-1.1169

P/CF

-1.1169

PEG

0.0831

P/S

8779.4886

EV Multiple

-0.5920

P/FV

2.3001

DPS

0.0000

Latest Headlines (EST)

No Headlines Found

Revenue Product Segmentation